{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:59:00Z","timestamp":1777373940243,"version":"3.51.4"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007161","name":"Boston University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA272637"],"award-info":[{"award-number":["R01 CA272637"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA232708"],"award-info":[{"award-number":["R01CA232708"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F30CA257566"],"award-info":[{"award-number":["F30CA257566"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM130546"],"award-info":[{"award-number":["T32GM130546"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA 227433"],"award-info":[{"award-number":["R01CA 227433"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA232056"],"award-info":[{"award-number":["R01CA232056"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA265713"],"award-info":[{"award-number":["U01CA265713"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.addr.2024.115331","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T15:26:05Z","timestamp":1715181965000},"page":"115331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Immunotherapies for locally aggressive cancers"],"prefix":"10.1016","volume":"210","author":[{"given":"Sarah C.","family":"Adams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun K.","family":"Nambiar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrajit P.","family":"Raut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolonda L.","family":"Colson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5453-3668","authenticated-orcid":false,"given":"Mark W.","family":"Grinstaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2024.115331_b0005","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3322\/caac.21498","article-title":"Local cancer recurrence: the realities, challenges, and opportunities for new therapies","volume":"68","author":"Mahvi","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"2024","key":"10.1016\/j.addr.2024.115331_b0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2024.115331_b0015","doi-asserted-by":"crossref","first-page":"16425","DOI":"10.1038\/s41598-020-73525-y","article-title":"The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data","volume":"10","author":"Bengtsson","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2024.115331_b0020","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1053\/ejso.2000.0945","article-title":"Prognostic factors predicting survival in the treatment of retroperitoneal sarcoma","volume":"26","author":"M\u00e4kel\u00e4","year":"2000","journal-title":"European J. Surgical Oncology (EJSO)"},{"key":"10.1016\/j.addr.2024.115331_b0025","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0030","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2024.115331_b0035","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/ijc.32931","article-title":"Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: a population-based study","volume":"147","author":"Sirri","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2024.115331_b0040","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1002\/cam4.2474","article-title":"Are 90% of deaths from cancer caused by metastases?","volume":"8","author":"Dillek\u00e5s","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.addr.2024.115331_b0045","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/S0140-6736(16)30354-3","article-title":"Gastric cancer","volume":"388","author":"Van Cutsem","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2024.115331_b0050","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"2016","key":"10.1016\/j.addr.2024.115331_b0055","first-page":"169","article-title":"Metastasis as an evolutionary process","volume":"352","author":"Turajlic","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.addr.2024.115331_b0060","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-3329-2-14","article-title":"The epidemiology of sarcoma","volume":"2","author":"Burningham","year":"2012","journal-title":"Clin Sarcoma Res."},{"key":"10.1016\/j.addr.2024.115331_b0065","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.addr.2024.115331_b0070","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.19.02806","article-title":"Multidisciplinary management of locoregional recurrent breast cancer","volume":"38","author":"Buchholz","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0075","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CCO.0000000000000697","article-title":"Malignant pleural mesothelioma: recent developments","volume":"33","author":"Sinn","year":"2021","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0080","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.791995","article-title":"Prior local or systemic treatment: a predictive model could guide clinical decision-making for locoregional recurrent breast cancer","volume":"11","author":"Wu","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0085","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.2017.74.6941","article-title":"Analysis of margin classification systems for assessing the risk of local recurrence after soft tissue sarcoma resection","volume":"36","author":"Gundle","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/SLA.0000000000001524","article-title":"The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer","volume":"264","author":"Harris","year":"2016","journal-title":"Ann. Surg."},{"key":"10.1016\/j.addr.2024.115331_b0095","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1984677","article-title":"Trial watch: intratumoral immunotherapy","volume":"10","author":"Humeau","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.addr.2024.115331_b0100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00262-020-02735-0","article-title":"Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives","volume":"70","author":"Qu","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.addr.2024.115331_b0105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.addr.2024.115331_b0110","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0115","doi-asserted-by":"crossref","unstructured":"A. RIZZO, G. FREGA, A.D. RICCI, A. PALLONI, F. ABBATI, S. DE LORENZO, M. DESERTI, S. TAVOLARI, G. BRANDI, Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis, In Vivo (Brooklyn) 34 (2020) 479\u2013488. doi.org\/10.21873\/invivo.11798.","DOI":"10.21873\/invivo.11798"},{"key":"10.1016\/j.addr.2024.115331_b0120","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0125","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13025","article-title":"Peptide-based therapeutic cancer vaccine: current trends in clinical application","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif"},{"key":"10.1016\/j.addr.2024.115331_b0130","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New England J. Medicine"},{"key":"10.1016\/j.addr.2024.115331_b0135","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti\u2013PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2024.115331_b0140","doi-asserted-by":"crossref","first-page":"xii18","DOI":"10.1093\/annonc\/mdx238","article-title":"Mechanisms regulating T-cell infiltration and activity in solid tumors","volume":"28","author":"Lanitis","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00258","article-title":"Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis","volume":"10","author":"Park","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0150","article-title":"CAR T-cell therapy: adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"J Adv Pract Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121299","article-title":"Precision biomaterials in cancer theranostics and modelling","volume":"280","author":"Caballero","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2024.115331_b0160","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1039\/D2BM01005D","article-title":"Advances in biomaterials for the treatment of retinoblastoma","volume":"10","author":"Farhat","year":"2022","journal-title":"Biomater Sci."},{"key":"10.1016\/j.addr.2024.115331_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2021.117696","article-title":"A comprehensive review on alginate-based delivery systems for the delivery of chemotherapeutic agent: doxorubicin","volume":"259","author":"Lakkakula","year":"2021","journal-title":"Carbohydr Polym."},{"key":"10.1016\/j.addr.2024.115331_b0170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.biomaterials.2016.01.061","article-title":"Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: a review","volume":"85","author":"Kanamala","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2024.115331_b0175","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1021\/acs.bioconjchem.5b00046","article-title":"Engineering biomaterial-drug conjugates for local and sustained chemotherapeutic delivery","volume":"26","author":"Coburn","year":"2015","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.addr.2024.115331_b0180","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2011.11.031","article-title":"Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers","volume":"159","author":"Wolinsky","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2024.115331_b0185","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/jbm.a.36912","article-title":"Recent advances in electrospun nanofiber- <scp>mediated drug<\/scp> delivery strategies for localized cancer chemotherapy","volume":"108","author":"Khodadadi","year":"2020","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.addr.2024.115331_b0190","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.msec.2016.01.063","article-title":"Biomaterial-based regional chemotherapy: local anticancer drug delivery to enhance chemotherapy and minimize its side-effects","volume":"62","author":"Krukiewicz","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.addr.2024.115331_b0195","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jconrel.2022.10.043","article-title":"The past, present, and future of chemotherapy with a focus on individualization of drug dosing","volume":"352","author":"DeRidder","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2024.115331_b0200","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201705328","article-title":"Advances in biomaterials for drug delivery","volume":"30","author":"Fenton","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2024.115331_b0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.actbio.2019.02.016","article-title":"Advances in immunotherapy delivery from implantable and injectable biomaterials","volume":"88","author":"Leach","year":"2019","journal-title":"Acta. Biomater."},{"key":"10.1016\/j.addr.2024.115331_b0210","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.it.2020.04.004","article-title":"Opportunities for small molecules in cancer immunotherapy","volume":"41","author":"van der Zanden","year":"2020","journal-title":"Trends. Immunol."},{"key":"10.1016\/j.addr.2024.115331_b0215","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrd4596","article-title":"Big opportunities for small molecules in immuno-oncology","volume":"14","author":"Adams","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2024.115331_b0220","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/cmdc.201500566","article-title":"Cancer immunotherapy: selected targets and small-molecule modulators","volume":"11","author":"Weinmann","year":"2016","journal-title":"ChemMedChem."},{"key":"10.1016\/j.addr.2024.115331_b0225","doi-asserted-by":"crossref","unstructured":"L. Jouhi, S. Renkonen, T. Atula, A. M\u00c3\u00a4kitie, C. Haglund, J. Hagstr\u00c3\u00b6m, Different Toll-Like Receptor Expression Patterns in Progression toward Cancer, Front Immunol 5 (2014). doi.org\/10.3389\/fimmu.2014.00638.","DOI":"10.3389\/fimmu.2014.00638"},{"key":"10.1016\/j.addr.2024.115331_b0230","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1080\/07853890.2022.2095664","article-title":"The role of toll-like receptors (TLRs) in pan-cancer","volume":"54","author":"Huang","year":"2022","journal-title":"Ann. Med."},{"key":"10.1016\/j.addr.2024.115331_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front Immunol."},{"key":"10.1016\/j.addr.2024.115331_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2022.100122","article-title":"The critical role of Toll-like receptor-mediated signaling in cancer immunotherapy","volume":"14","author":"Chen","year":"2022","journal-title":"Med Drug Discov."},{"key":"10.1016\/j.addr.2024.115331_b0245","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1067\/mjd.2001.113689","article-title":"Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial","volume":"44","author":"Marks","year":"2001","journal-title":"J. Am Acad. Dermatol."},{"key":"10.1016\/j.addr.2024.115331_b0250","doi-asserted-by":"crossref","first-page":"13168","DOI":"10.1021\/acsnano.2c06300","article-title":"Nanocarrier Co-formulation for delivery of a TLR7 agonist plus an immunogenic cell death stimulus triggers effective pancreatic cancer chemo-immunotherapy","volume":"16","author":"Luo","year":"2022","journal-title":"ACS Nano."},{"key":"10.1016\/j.addr.2024.115331_b0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar1916","article-title":"Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases","volume":"10","author":"Park","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2024.115331_b0260","article-title":"A surgically optimized intraoperative poly(I:C)-releasing hydrogel prevents cancer recurrence","volume":"4","author":"Rwandamuriye","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.addr.2024.115331_b0265","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","article-title":"The cGAS\u2013STING pathway as a therapeutic target in inflammatory diseases","volume":"21","author":"Decout","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.addr.2024.115331_b0270","article-title":"Cytoplasmic DNAs: sources, sensing, and roles in the development of lung inflammatory diseases and cancer","volume":"14","author":"He","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.addr.2024.115331_b0275","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-021-00554-y","article-title":"Cytosolic DNA sensing by cGAS: regulation, function, and human diseases","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.addr.2024.115331_b0280","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ccell.2018.05.013","article-title":"Cytosolic DNA sensing in organismal tumor control","volume":"34","author":"Vanpouille-Box","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2024.115331_b0285","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.apsb.2020.03.001","article-title":"Small molecules targeting the innate immune cGAS-STING-TBK1 signaling pathway","volume":"10","author":"Ding","year":"2020","journal-title":"Acta. Pharm Sin B"},{"key":"10.1016\/j.addr.2024.115331_b0290","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1158\/1538-7445.AM2018-5554","article-title":"Abstract 5554: Preclinical characterization of GSK532, a novel STING agonist with potent anti-tumor activity","volume":"78","author":"Yang","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2024.115331_b0295","first-page":"232","article-title":"Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy","volume":"16","author":"Wang","year":"2022","journal-title":"Bioact Mater."},{"key":"10.1016\/j.addr.2024.115331_b0300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz6606","article-title":"Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy","author":"Lu","year":"2020","journal-title":"ScienceTranslational Medicine"},{"key":"10.1016\/j.addr.2024.115331_b0305","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.nano.2017.10.013","article-title":"Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy","volume":"14","author":"Wilson","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.addr.2024.115331_b0310","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41551-020-0597-7","article-title":"Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel","volume":"4","author":"Wang","year":"2020","journal-title":"Nat. Biomed Eng."},{"key":"10.1016\/j.addr.2024.115331_b0315","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.addr.2024.115331_b0320","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/s41388-021-01811-8","article-title":"Antibody-based cancer therapy","volume":"40","author":"Goydel","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.addr.2024.115331_b0325","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of therapeutic antitumor monoclonal antibodies","volume":"81","author":"Tsao","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2024.115331_b0330","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.addr.2024.115331_b0335","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","article-title":"Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry","volume":"17","author":"McCombs","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.addr.2024.115331_b0340","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.3390\/molecules26102943","article-title":"Antibody-drug conjugates\u2014a tutorial review","volume":"26","author":"Baah","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2024.115331_b0345","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J. Hematol Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0350","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","article-title":"CAR-T cells and BiTEs in solid tumors: challenges and perspectives","volume":"14","author":"Edeline","year":"2021","journal-title":"J. Hematol Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0355","unstructured":"Bispecific Antibodies: An Area of Research and Clinical Applications | FDA, US Food & Drug Administration (2024). https:\/\/www.fda.gov\/drugs\/spotlight-cder-science\/bispecific-antibodies-area-research-and-clinical-applications (accessed March 14, 2024)."},{"key":"10.1016\/j.addr.2024.115331_b0360","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ijbiomac.2020.11.058","article-title":"Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: recent advances and clinical trials","volume":"167","author":"Hosseini","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2024.115331_b0365","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrd4363","article-title":"Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies","volume":"13","author":"Mitragotri","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2024.115331_b0370","article-title":"Designer protein delivery: From natural to engineered affinity-controlled release systems","volume":"351","author":"Pakulska","year":"2016","journal-title":"Science (1979)"},{"key":"10.1016\/j.addr.2024.115331_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119358","article-title":"Polymers for cytosolic protein delivery","volume":"218","author":"Lv","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2024.115331_b0380","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jconrel.2015.10.012","article-title":"Nanotechnology for protein delivery: overview and perspectives","volume":"240","author":"Yu","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2024.115331_b0385","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1517\/17425247.2015.961420","article-title":"Long-term delivery of protein therapeutics","volume":"12","author":"Vaishya","year":"2015","journal-title":"Expert Opin Drug Deliv."},{"key":"10.1016\/j.addr.2024.115331_b0390","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2020.08.008","article-title":"Recent trends in protein and peptide-based biomaterials for advanced drug delivery","volume":"156","author":"Varanko","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2024.115331_b0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2021.04.002","article-title":"Sustained release of peptides and proteins from polymeric nanocarriers produced by inverse flash nanoprecipitation","volume":"334","author":"Markwalter","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2024.115331_b0400","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/17460441.2019.1614910","article-title":"Recent applications of click chemistry in drug discovery","volume":"14","author":"Jiang","year":"2019","journal-title":"Expert Opin Drug Discov."},{"key":"10.1016\/j.addr.2024.115331_b0405","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5","article-title":"Click chemistry: diverse chemical function from a few good reactions","volume":"40","author":"Kolb","year":"2001","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.addr.2024.115331_b0410","doi-asserted-by":"crossref","DOI":"10.1186\/s40824-018-0123-0","article-title":"Application of click chemistry in nanoparticle modification and its targeted delivery","volume":"22","author":"Yi","year":"2018","journal-title":"Biomater Res."},{"key":"10.1016\/j.addr.2024.115331_b0415","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1039\/C5BM00052A","article-title":"Protein nanoparticles for therapeutic protein delivery","volume":"3","author":"Herrera Estrada","year":"2015","journal-title":"Biomater Sci."},{"key":"10.1016\/j.addr.2024.115331_b0420","doi-asserted-by":"crossref","first-page":"e18758","DOI":"10.1371\/journal.pone.0018758","article-title":"Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth","volume":"6","author":"Kar","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2024.115331_b0425","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201701469","article-title":"Injectable, tough alginate cryogels as cancer vaccines","volume":"7","author":"Shih","year":"2018","journal-title":"Adv. Healthc Mater"},{"key":"10.1016\/j.addr.2024.115331_b0430","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201704107","article-title":"Thermogelling, ABC triblock copolymer platform for resorbable hydrogels with tunable, degradation-mediated drug release","volume":"27","author":"Gupta","year":"2017","journal-title":"Adv. Funct Mater"},{"key":"10.1016\/j.addr.2024.115331_b0435","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1600519","article-title":"Encapsulation-free controlled release: electrostatic adsorption eliminates the need for protein encapsulation in PLGA nanoparticles","volume":"2","author":"Pakulska","year":"2016","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2024.115331_b0440","article-title":"Logic-based delivery of site-specifically modified proteins from environmentally responsive hydrogel biomaterials","volume":"31","author":"Gawade","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2024.115331_b0445","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41565-018-0319-4","article-title":"In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Nanotechnol"},{"key":"10.1016\/j.addr.2024.115331_b0450","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jconrel.2022.05.040","article-title":"Real-time evaluation of a hydrogel delivery vehicle for cancer immunotherapeutics within embedded spheroid cultures","volume":"348","author":"Huynh","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2024.115331_b0455","doi-asserted-by":"crossref","first-page":"35309","DOI":"10.1021\/acsami.2c06137","article-title":"A shear-thinning biomaterial-mediated immune checkpoint blockade","volume":"14","author":"Wu","year":"2022","journal-title":"ACS Appl. Mater Interfaces"},{"key":"10.1016\/j.addr.2024.115331_b0460","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1021\/acsbiomaterials.0c00840","article-title":"Biodegradable implants combined with immunogenic chemotherapy and immune checkpoint therapy for peritoneal metastatic carcinoma postoperative treatment","volume":"6","author":"Si","year":"2020","journal-title":"ACS Biomater Sci. Eng."},{"key":"10.1016\/j.addr.2024.115331_b0465","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0560.2010.01506.x","article-title":"The biologic importance of tumor-infiltrating lymphocytes","volume":"37","author":"Hodi","year":"2010","journal-title":"J. Cutan Pathol"},{"key":"10.1016\/j.addr.2024.115331_b0470","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.addr.2024.115331_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101134","article-title":"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis","volume":"41","author":"Li","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.addr.2024.115331_b0480","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2326-6066.CIR-15-0143","article-title":"Reflections on the histopathology of tumor-infiltrating lymphocytes in melanoma and the host immune response","volume":"3","author":"Mihm","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.addr.2024.115331_b0485","unstructured":"C. (Kempler) Pflaum, FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma | FDA, U.S. Food & Drug Administrtion (2024). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cellular-therapy-treat-patients-unresectable-or-metastatic-melanoma (accessed March 13, 2024)."},{"key":"10.1016\/j.addr.2024.115331_b0490","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.omto.2021.07.006","article-title":"Prognostic and therapeutic TILs of cervical cancer\u2014current advances and future perspectives","volume":"22","author":"Tang","year":"2021","journal-title":"Mol. Ther Oncolytics"},{"key":"10.1016\/j.addr.2024.115331_b0495","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0500","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nbt.3104","article-title":"Biopolymer implants enhance the efficacy of adoptive T-cell therapy","volume":"33","author":"Stephan","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"2022","key":"10.1016\/j.addr.2024.115331_b0505","first-page":"853","article-title":"The future of engineered immune cell therapies","volume":"378","author":"Irvine","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.addr.2024.115331_b0510","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2024.115331_b0515","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.addr.2024.115331_b0520","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1016\/j.addr.2024.115331_b0525","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0530","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.addr.2024.115331_b0535","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.addr.2024.115331_b0540","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2024.115331_b0545","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1\u2013 and CTLA-4\u2013Based Inhibitory Chimeric Antigen Receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci. Transl Med."},{"key":"10.1016\/j.addr.2024.115331_b0550","article-title":"Remote control of therapeutic T cells through a small molecule\u2013gated chimeric receptor","volume":"350","author":"Wu","year":"2015","journal-title":"Science (1979)"},{"key":"10.1016\/j.addr.2024.115331_b0555","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","article-title":"Enhanced safety and efficacy of protease-regulated CAR-T cell receptors","volume":"185","author":"Labanieh","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.addr.2024.115331_b0560","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","article-title":"High-performance multiplex drug-gated CAR circuits","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2024.115331_b0565","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0570","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.addr.2024.115331_b0575","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","article-title":"Engineering advanced logic and distributed computing in human CAR immune cells","volume":"12","author":"Cho","year":"2021","journal-title":"Nat. Commun"},{"key":"10.1016\/j.addr.2024.115331_b0580","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","article-title":"Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets","volume":"5","author":"Hu","year":"2021","journal-title":"Nat. Biomed Eng."},{"key":"10.1016\/j.addr.2024.115331_b0585","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn8264","article-title":"Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors","volume":"8","author":"Grosskopf","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2024.115331_b0590","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg5841","article-title":"Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma","volume":"7","author":"Ogunnaike","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2024.115331_b0595","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade2526","article-title":"Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma","volume":"9","author":"Uslu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2024.115331_b0600","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41565-020-00813-z","article-title":"DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation","volume":"16","author":"Huang","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2024.115331_b0605","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1172\/JCI87624","article-title":"Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors","volume":"127","author":"Smith","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.addr.2024.115331_b0610","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41551-019-0486-0","article-title":"Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours","volume":"4","author":"Coon","year":"2019","journal-title":"Nat. Biomed Eng."},{"issue":"2019","key":"10.1016\/j.addr.2024.115331_b0615","first-page":"162","article-title":"Enhanced CAR\u2013T cell activity against solid tumors by vaccine boosting through the chimeric receptor","volume":"365","author":"Ma","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.addr.2024.115331_b0620","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jtct.2022.06.025","article-title":"The next generation of cellular immunotherapy: chimeric antigen receptor-natural killer cells","volume":"28","author":"Moscarelli","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.addr.2024.115331_b0625","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J. Leukoc Biol."},{"key":"10.1016\/j.addr.2024.115331_b0630","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J. Hematol Oncol."},{"key":"10.1016\/j.addr.2024.115331_b0635","unstructured":"A Multicenter Phase I Trial on the Safety and Preliminary Efficacy of DLL3-CAR-NK Cells in the Treatment of Relapsed \/ Refractory Extensive Stage Small Cell Lung Cancer, ClinicalTrials.Gov Identifier NCT05507593. U.S. National Library of Medicine, 2022 (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT05507593 (accessed January 20, 2024)."},{"key":"10.1016\/j.addr.2024.115331_b0640","unstructured":"NKG2D CAR-NK Cell Therapy for Patients With Platinum-Resistant Recurrent Ovarian Cancer, ClinicalTrials.Gov Identifier NCT05776355. U.S. National Library of Medicine, 2023 (n.d.). https:\/\/www.clinicaltrials.gov\/study\/NCT05776355?term=NCT05776355&rank=1 (accessed January 20, 2024)."},{"key":"10.1016\/j.addr.2024.115331_b0645","unstructured":"W. Fang, NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer, ClinicalTrials.Gov Identifier NCT05213195. U.S. National Library of Medicine, 2023 (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT05213195 (accessed January 20, 2024)."},{"key":"10.1016\/j.addr.2024.115331_b0650","unstructured":"H. Huang, NKG2D CAR-NK Cell Therapy for the Treatment of Patients With Relapsed and\/or Refractory Acute Myeloid Leukemia, ClinicalTrials.Gov Identifier NCT05734898. U.S. National Library of Medicine, 2023 (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT05734898 (accessed January 20, 2024)."},{"key":"10.1016\/j.addr.2024.115331_b0655","unstructured":"Safety and Efficacy of Anti-CD19 CAR-Engineered NK Cells for Relapsed\/Refractory B-cell Malignancies: a Multi-center, Open-label, Single-arm Clinical Study, ClinicalTrials.Gov Identifier NCT05410041. U.S. National Library of Medicine 2022 (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT05410041 (accessed January 20, 2024)."},{"key":"10.1016\/j.addr.2024.115331_b0660","unstructured":"A Early Phase 1 Clinical Trial to Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With Relapsed\/Refractory Multiple Myeloma or Plasma Cell Leukemia, ClinicalTrials.Gov Identifier NCT06045091. U.S. National Library of Medicine, 2023 (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT06045091 (accessed January 20, 2024)."},{"key":"10.1016\/j.addr.2024.115331_b0665","unstructured":"H. Huang, RD13-01 for Patients With r\/r CD7+ T\/NK Cell Hematologic Malignancies, ClinicalTrials.Gov Identifier NCT04538599. U.S. National Library of Medicine 2022 (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT04538599 (accessed January 20, 2024)."},{"key":"10.1016\/j.addr.2024.115331_b0670","unstructured":"Dose Escalation Study Phase I\/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed\/Refractory B-Lymphoid Malignancies, ClinicalTrials.Gov Identifier NCT03056339. U.S. National Library of Medicine, 2023 (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT03056339 (accessed January 23, 2024)."},{"key":"10.1016\/j.addr.2024.115331_b0675","unstructured":"A Phase \u2160 Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor Gene Modified NK Cells Targeting CD19 in Patients With Recurrent or Refractory CD19 Positive Acute Lymphoblastic Leukemia, ClinicalTrials.Gov Identifier NCT05563545. U.S. National Library of Medicine 2022 (n.d.). https:\/\/clinicaltrials.gov\/study\/NCT05563545 (accessed January 23, 2024)."},{"key":"10.1016\/j.addr.2024.115331_b0680","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.ymthe.2019.03.011","article-title":"Adoptive transfer of NKG2D CAR mRNA-engineered natural killer cells in colorectal cancer patients","volume":"27","author":"Xiao","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2024.115331_b0685","article-title":"Preclinical and clinical studies of CAR-NK-cell therapies for malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.addr.2024.115331_b0690","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40364-023-00537-x","article-title":"The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors","volume":"11","author":"Hadiloo","year":"2023","journal-title":"Biomark Res."},{"key":"10.1016\/j.addr.2024.115331_b0695","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","article-title":"Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix","volume":"121","author":"Zhang","year":"2019","journal-title":"Br J. Cancer"},{"key":"10.1016\/j.addr.2024.115331_b0700","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.addr.2024.115331_b0705","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2024.115331_b0710","doi-asserted-by":"crossref","unstructured":"Y. Abdou, E.C. Dees, J.E. Mortimer, P.R. Pohlmann, M.L. Johnson, R.T. Maziarz, J.M. Specht, Y. Yuan, N.T. Ueno, M. Angelos, S. Gill, A. Ronczka, T. Condamine, D. Cushing, D. Barton, M. Klichinsky, R.F. Swaby, K.A. Reiss. (2023) A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors., Https:\/\/Doi.Org\/10.1200\/JCO.2023.41.16_suppl.TPS2666 41. TPS2666\u2013TPS2666. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_SUPPL.TPS2666.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2666"},{"key":"10.1016\/j.addr.2024.115331_b0715","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202000275","article-title":"Scaffold-mediated static transduction of T Cells for CAR-T cell therapy","volume":"9","author":"Agarwalla","year":"2020","journal-title":"Adv. Healthc Mater"},{"key":"10.1016\/j.addr.2024.115331_b0720","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2017.750","article-title":"Intraoperative radiotherapy: review of techniques and results","volume":"11","author":"Pilar","year":"2017","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.addr.2024.115331_b0725","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijrobp.2016.10.034","article-title":"Smart radiation therapy biomaterials","volume":"97","author":"Ngwa","year":"2017","journal-title":"Int. J. Radiat Oncol. Biol. Phys."},{"key":"10.1016\/j.addr.2024.115331_b0730","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1021\/acs.chemrev.1c00622","article-title":"Ultrasound-responsive systems as components for smart materials","volume":"122","author":"Athanassiadis","year":"2022","journal-title":"Chem. Rev."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X24001534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X24001534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T22:41:57Z","timestamp":1717886517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X24001534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":146,"alternative-id":["S0169409X24001534"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2024.115331","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapies for locally aggressive cancers","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2024.115331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115331"}}